Teach me everything about fasting lipid profile it's values and it's significance, differential diagnosis and medications to use in different conditions
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Finding Sources
Searching the Web
fasting lipid profile normal values LDL HDL cholesterol triglycerides reference ranges 2024
I now have comprehensive data from multiple authoritative textbooks. Let me compile a thorough, well-organized answer.
Fasting Lipid Profile: Complete Guide
1. What Is a Fasting Lipid Profile?
A fasting lipid profile (also called a lipid panel or lipoprotein panel) is a blood test obtained after a 12-14 hour fast that measures the four major lipid fractions in plasma. It is the standard tool for cardiovascular risk assessment and dyslipidemia diagnosis.
Components measured:
- Total Cholesterol (TC)
- LDL Cholesterol (LDL-C) - usually calculated via Friedewald equation
- HDL Cholesterol (HDL-C)
- Triglycerides (TG)
- VLDL Cholesterol (derived: TG ÷ 5)
- Non-HDL Cholesterol (derived: TC - HDL-C)
Why fasting? Triglycerides rise significantly after a meal (postprandial lipemia). Fasting ensures accurate LDL calculation (Friedewald equation: LDL = TC - HDL - TG/5) and reliable TG measurement. A non-fasting panel can be used if fasting is impractical, but a fasting panel is required if non-HDL-C ≥ 220 mg/dL or TG ≥ 500 mg/dL. - The Washington Manual of Medical Therapeutics
2. Normal Reference Values (Adults)
| Component | Desirable / Normal | Borderline / At Risk | High / Abnormal |
|---|---|---|---|
| Total Cholesterol | < 200 mg/dL | 200-239 mg/dL (borderline high) | ≥ 240 mg/dL (high) |
| LDL-C | < 100 mg/dL (optimal) | 100-129 mg/dL (near optimal) 130-159 mg/dL (borderline high) | 160-189 mg/dL (high) ≥ 190 mg/dL (very high) |
| HDL-C | ≥ 60 mg/dL (protective) Men: ≥ 40 mg/dL Women: ≥ 50 mg/dL | 41-59 mg/dL | < 40 mg/dL (men) / < 50 mg/dL (women) = LOW = risk factor |
| Triglycerides | < 150 mg/dL (normal) | 150-199 mg/dL (borderline high) | 200-499 mg/dL (high) ≥ 500 mg/dL (very high) |
| VLDL-C | 2-30 mg/dL | - | > 30 mg/dL |
| Non-HDL-C | < 130 mg/dL | 130-159 mg/dL | ≥ 160 mg/dL |
Risk Factor Notes:
- Low HDL-C (< 40 mg/dL in men, < 50 mg/dL in women) is an independent cardiovascular risk factor
- Non-HDL-C ≥ 220 mg/dL suggests a genetic or secondary cause
- TG > 500 mg/dL dramatically increases risk of acute pancreatitis (10-fold risk vs. TG < 88 mg/dL) - Fuster and Hurst's The Heart, 15th Edition
- TG > 440 mg/dL carries approximately 5-fold increased MI risk and 3-fold stroke risk
For children:
| Component | Desirable | Borderline | High |
|---|---|---|---|
| Total Cholesterol | < 170 mg/dL | 170-199 | ≥ 200 |
| LDL-C | < 110 mg/dL | 110-129 | ≥ 130 |
| Triglycerides (0-9 yr) | < 75 mg/dL | 75-99 | ≥ 100 |
| Triglycerides (10-19 yr) | < 90 mg/dL | 90-129 | ≥ 130 |
3. Pathophysiology of Lipoproteins
LDL-C (Low-Density Lipoprotein)
- Carries ~60-70% of total cholesterol in blood
- Delivers cholesterol to peripheral tissues and arterial walls
- Crosses the endothelial barrier and initiates atherosclerosis by depositing cholesterol in the arterial intima
- Cleared from circulation by hepatic LDL receptors
- Statins upregulate LDL receptors, enhancing LDL clearance - Goodman & Gilman's
HDL-C (High-Density Lipoprotein)
- Mediates reverse cholesterol transport: removes cholesterol from peripheral tissues back to the liver
- Protective against ASCVD
- HDL generated partly from phospholipid/apo A-I shed during chylomicron lipolysis
Triglycerides / VLDL / Remnants
- VLDL produced by liver, carries TG to peripheral tissues
- Hydrolyzed by lipoprotein lipase (LPL) to IDL, then LDL
- TG-rich lipoprotein remnants (chylomicron remnants + VLDL remnants) are independently atherogenic
- Elevated TG = elevated remnant cholesterol = elevated ASCVD risk - Fuster and Hurst's The Heart, 15th Edition
4. Clinical Significance
A. Cardiovascular Risk
- Every 1 mmol/L (38.5 mg/dL) rise in LDL-C increases ASCVD risk proportionally
- The Framingham Study, MRFIT, and Seven Countries Study all confirmed: as total cholesterol rises, CAD risk rises - Textbook of Family Medicine 9e
- VLDL and LDL particles both induce atherogenesis - Textbook of Family Medicine 9e
B. Pancreatitis Risk
- TG ≥ 500 mg/dL: significant pancreatitis risk
- TG > 1000-2000 mg/dL: severe/life-threatening pancreatitis risk
C. ASCVD Risk Stratification (2018 ACC/AHA Guidelines)
- Primary Prevention (ages 40-75):
- LDL-C ≥ 190 mg/dL: High-intensity statin regardless of risk score
- DM: Moderate-intensity statin regardless of risk score
- 10-yr ASCVD ≥ 20% (high risk): LDL reduction ≥ 50%
- 10-yr ASCVD 7.5%-19.9% (intermediate): LDL reduction 30-49%
- 10-yr ASCVD 5%-7.5% (borderline): moderate statin may be considered
- 10-yr ASCVD < 5% (low risk): lifestyle only
- Secondary Prevention:
- All known ASCVD: High-intensity statin, LDL goal < 70 mg/dL
- Very-high-risk ASCVD: LDL threshold of 70 mg/dL to add nonstatin agents
5. Differential Diagnosis of Dyslipidemia
A. Primary (Genetic) Causes
| Disorder | Key Lipid Abnormality | Notes |
|---|---|---|
| Familial Hypercholesterolemia (FH) | Very high LDL-C (often > 190 mg/dL) | Autosomal codominant; prevalence 1:200; LDL receptor mutation; tendon xanthomas |
| Familial Combined Hyperlipidemia | Elevated LDL + TG | Prevalence 1-2%; presents in adulthood; worsened by obesity/high fat/sugar diet |
| Familial Hypertriglyceridemia | Elevated TG | Often mild-moderate; TG > 500 mg/dL; pancreatitis risk |
| Familial Chylomicronemia Syndrome | Massive TG elevation (> 1000 mg/dL) | LPL deficiency or apo C-II deficiency; autosomal recessive; presents before puberty |
| Type III Hyperlipoproteinemia (Dysbetalipoproteinemia) | Elevated TG + cholesterol | ApoE2 homozygosity; elevated remnants |
| Tangier Disease | Very low HDL-C | ABCA1 mutation |
| LCAT Deficiency | Low HDL-C | Lecithin-cholesterol acyltransferase deficiency |
- Washington Manual: FH onset before puberty suggests LPL or apo C-II deficiency (autosomal recessive)
B. Secondary (Acquired) Causes
| Secondary Cause | Elevated LDL-C | Elevated TG |
|---|---|---|
| Diet | Saturated/trans fats, anorexia, weight gain | High refined carbs, excessive alcohol, weight gain, very low-fat diets |
| Hypothyroidism | Yes | Yes |
| Diabetes Mellitus (poorly controlled) | - | Yes (major cause) |
| Nephrotic Syndrome | Yes | Yes |
| Chronic Kidney Disease | - | Yes |
| Biliary Obstruction / Cholestasis | Yes | - |
| Obesity | Yes | Yes |
| Pregnancy | Yes (progressive rise) | Yes |
| Lipodystrophy | - | Yes |
| Hypothyroidism | Yes | Yes |
| Cushing's Syndrome / Glucocorticoids | Yes | Yes |
Drug-Induced Dyslipidemia:
| Drug | Effect on LDL | Effect on TG | Effect on HDL |
|---|---|---|---|
| Beta-blockers (non-selective) | - | ↑ | ↓ |
| Thiazide diuretics | - | ↑ | ↓ |
| Oral estrogens | - | ↑↑ | ↑ |
| Glucocorticoids | ↑ | ↑ | - |
| Cyclosporine | ↑ | - | - |
| Amiodarone | ↑ | - | - |
| Protease inhibitors (HIV) | ↑ | ↑↑ (ritonavir can cause TG > 1000) | ↓ |
| Retinoids/retinoic acid | - | ↑ | - |
| Anabolic steroids | ↑ | ↑ | ↓↓ |
| Atypical antipsychotics | ↑ | ↑ | ↓ |
| Sirolimus, raloxifene, tamoxifen | - | ↑ | - |
| Bile acid sequestrants | - | ↑ | - |
Source: Textbook of Family Medicine 9e; Braunwald's Heart Disease
When evaluating dyslipidemia, always rule out: hypothyroidism, DM, obstructive liver disease, CKD/nephrotic syndrome, and drug causes. - Washington Manual
6. Treatment Approach and Medications
A. Lifestyle Modifications (First-Line for All)
- Diet: Saturated fat < 5-6% of calories; increase fruits, vegetables, whole grains, fish, lean meat, nuts; reduce red meat, trans fats, refined sugars
- Polyunsaturated fat replaces saturated fat: lowers LDL-C and TG
- Viscous fiber and plant stanols: reduce cholesterol absorption
- Exercise: ≥ 150 min/week moderate-intensity aerobic activity; reduces TG, raises HDL
- Weight loss 5-10%: improves all lipid parameters, delays T2DM
- Smoking cessation
- Limit alcohol (reduces TG)
B. Pharmacological Therapy
1. Statins (HMG-CoA Reductase Inhibitors) - FIRST-LINE for LDL lowering
Mechanism: Competitively inhibit HMG-CoA reductase → reduce hepatic cholesterol synthesis → upregulate LDL receptors → increase LDL clearance
| Intensity | Drugs & Doses | LDL Reduction |
|---|---|---|
| High-Intensity | Atorvastatin 40-80 mg, Rosuvastatin 20-40 mg | ≥ 50% |
| Moderate-Intensity | Atorvastatin 10-20 mg, Rosuvastatin 5-10 mg, Simvastatin 20-40 mg, Pravastatin 40-80 mg, Lovastatin 40 mg, Pitavastatin 1-4 mg, Fluvastatin XL 80 mg | 30-49% |
| Low-Intensity | Simvastatin 10 mg, Pravastatin 10-20 mg, Lovastatin 20 mg, Fluvastatin 20-40 mg | < 30% |
Indications:
- Clinical ASCVD (secondary prevention) - high-intensity
- LDL-C ≥ 190 mg/dL - high-intensity
- DM, age 40-75 - moderate (or high if risk ≥ 7.5%)
- Primary prevention, 10-yr ASCVD ≥ 7.5%, age 40-75
Special notes:
- Gemfibrozil + statins: avoid (increased myopathy risk)
- Simvastatin max 20 mg with amlodipine or amiodarone; max 10 mg with diltiazem or verapamil
- Rosuvastatin and pravastatin better tolerated (less myalgia)
- Lovastatin: take with evening meal (better absorption)
- Small increased risk of new-onset T2DM; ASCVD benefits outweigh this risk
Source: Goodman & Gilman's; Washington Manual
2. Ezetimibe - ADD-ON to Statins
Mechanism: Inhibits Niemann-Pick C1-like 1 (NPC1L1) protein in intestinal brush border → blocks cholesterol absorption → reduces intestinal cholesterol delivery to liver → upregulates LDL receptors
- LDL-C reduction: ~15-20% additional on top of statin
- Used when LDL-C remains > 100 mg/dL despite high-intensity statin
Indication: Step 2 add-on in very-high-risk ASCVD, FH, or residual high LDL on maximal statin
3. PCSK9 Inhibitors - MOST POWERFUL LDL-Lowering
Drugs: Evolocumab (Repatha), Alirocumab (Praluent) - monoclonal antibodies
Mechanism: Inhibit PCSK9 → prevent LDL receptor degradation → more LDL receptors available → dramatic LDL-C reduction (50-60% additional)
- Increase LDL receptor expression by suppressing PCSK9-mediated receptor degradation
Indications:
- Very-high-risk ASCVD with LDL-C > 70 mg/dL despite maximally tolerated statin + ezetimibe
- Heterozygous or homozygous FH
- Add after ezetimibe before PCSK9 inhibitor
4. Bile Acid Sequestrants (Resins)
Drugs: Cholestyramine, Colestipol, Colesevelam
Mechanism: Bind bile acids in gut → interrupt enterohepatic circulation → liver uses cholesterol to make new bile acids → upregulates LDL receptors
- LDL-C reduction: 15-30%
- Raise TG - avoid in hypertriglyceridemia
- Useful in pregnancy (not absorbed systemically)
- Drug interactions: impair absorption of fat-soluble vitamins, digoxin, warfarin, thyroxine
5. Fibrates (Fibric Acid Derivatives)
Drugs: Gemfibrozil, Fenofibrate, Bezafibrate
Mechanism: Activate PPAR-alpha → increase LPL activity → enhanced TG hydrolysis; increase HDL; reduce VLDL synthesis
- Primary use: Hypertriglyceridemia (TG > 500 mg/dL)
- TG reduction: 30-50%
- HDL increase: 10-20%
- Modest LDL reduction (or may increase LDL in severe hypertriglyceridemia)
- Avoid gemfibrozil + statin (severe myopathy/rhabdomyolysis risk); fenofibrate is safer with statins
Indications:
- TG ≥ 500 mg/dL (pancreatitis prevention)
- Combined hyperlipidemia (with statin)
- Fenofibrate preferred over gemfibrozil when statin is co-prescribed
6. Niacin (Nicotinic Acid)
Mechanism: Reduces hepatic VLDL synthesis and TG secretion; raises HDL-C most effectively of all drugs
- TG reduction: 20-50%
- HDL increase: 15-35% (most potent HDL raiser)
- LDL reduction: 10-25%
- Adverse effects: Flushing (take aspirin 30 min before), hepatotoxicity, hyperglycemia, hyperuricemia, worsens insulin resistance
- AIM-HIGH trial showed niacin did not reduce CV events when added to intensive statin therapy
- Largely fallen out of favor; used mainly for severe hypertriglyceridemia or very low HDL
7. Omega-3 Fatty Acids
Drugs: Icosapentaenoic acid (EPA) - Vascepa (high-purity EPA), Omega-3 acid ethyl esters (Lovaza)
Mechanism: Reduce hepatic TG synthesis and secretion; reduce VLDL
- TG reduction: 20-30%
- REDUCE-IT trial: Icosapentaenoic acid (4g/day) reduced CV events by 25% in patients with elevated TG on statins
- Indication: TG ≥ 150 mg/dL as add-on to statin; TG > 500 mg/dL
8. Drugs for Homozygous FH (Rare/Severe)
| Drug | Mechanism | Notes |
|---|---|---|
| Lomitapide | MTP (microsomal triglyceride transfer protein) inhibitor → reduces VLDL/chylomicron assembly | For homozygous FH; hepatotoxicity risk |
| Mipomersen | ApoB antisense oligonucleotide → reduces apoB-100 synthesis | For homozygous FH; injection site reactions, hepatic steatosis |
| Inclisiran | siRNA silencing of PCSK9 gene in hepatocytes | Twice-yearly injection; newer agent |
| LDL Apheresis | Extracorporeal removal of LDL | Homozygous FH; severe HeFH unresponsive to medications |
Source: Washington Manual; Goodman & Gilman's
C. Treatment by Clinical Scenario Summary
| Condition | First-Line | Add-On if Needed |
|---|---|---|
| Clinical ASCVD (Secondary Prevention) | High-intensity statin (atorvastatin 40-80 mg OR rosuvastatin 20-40 mg); LDL goal < 70 mg/dL | Ezetimibe → PCSK9 inhibitor |
| Very High-Risk ASCVD (multiple events or events + risk factors) | High-intensity statin; LDL goal < 55 mg/dL | Add ezetimibe, then PCSK9 inhibitor if still > 70 |
| LDL-C ≥ 190 mg/dL (FH) | High-intensity statin | If LDL > 100 on statin: add ezetimibe; if still > 100: PCSK9 inhibitor; LDL apheresis for homozygous FH |
| DM, age 40-75 | Moderate-intensity statin | High-intensity if ASCVD risk ≥ 7.5% |
| Primary Prevention, 10-yr risk ≥ 7.5% | Moderate-intensity statin | High-intensity if risk > 20% |
| Isolated Hypertriglyceridemia (TG 150-499) | Lifestyle, omega-3, statin | Fibrate |
| Severe Hypertriglyceridemia (TG ≥ 500) | Fibrate (fenofibrate/gemfibrozil) + strict diet + omega-3 | - |
| Low HDL-C | Lifestyle (exercise, weight loss, smoking cessation) | Niacin (limited benefit in trials) |
| Mixed Hyperlipidemia (↑ LDL + ↑ TG) | Statin | Add fenofibrate (safer than gemfibrozil with statins) or omega-3 |
| Hypothyroidism-Induced | Treat hypothyroidism first; lipids often normalize | Statin if persists |
| Pregnancy | Lifestyle only (statins, niacin, ezetimibe all contraindicated) | Bile acid sequestrants if needed |
D. Screening Recommendations (ACC/AHA 2018)
- All adults age ≥ 20: fasting lipid profile
- Repeat every 4-6 years in adults 40-75 without ASCVD indication
- Acute coronary syndrome / revascularization: lipid panel within 24 hours of admission
- Start statin therapy discussions in adults age 40-75 based on PCE (Pooled Cohort Equation) at tools.acc.org/ASCVD-Risk-Estimator-Plus/
7. Key Formulas
- LDL-C (Friedewald): LDL = TC - HDL - (TG/5) [valid only when TG < 400 mg/dL]
- Non-HDL-C: TC - HDL-C [captures all atherogenic particles]
- VLDL-C: TG ÷ 5
- TC:HDL ratio: Cardiovascular risk marker; optimal < 3.5:1; concerning > 5:1
- TG:HDL ratio: Marker of insulin resistance; < 1.0 optimal; > 3.0 suggests insulin resistance
Sources:
- The Washington Manual of Medical Therapeutics
- Goodman & Gilman's The Pharmacological Basis of Therapeutics
- Fuster and Hurst's The Heart, 15th Edition
- Textbook of Family Medicine, 9th Edition
- UCSF Health / Healthline reference ranges
- 2018 ACC/AHA Cholesterol Management Guidelines
This is a shared conversation. Sign in to Orris to start your own chat.